investor-relations@ucb.com or a specific team member: Antje Witte, VP Investor Relations Tel: +32 2 559 9414 E-mail: Antje.Witte@ucb.com; Isabelle Ghellynck, Associate Director Investor Relations Tel: +32 2 559 9588 E-mail: Isabelle.Ghellynck@ucb.com; Nathalie Deldime, Investor Relations Events Manager Tel: +32 2 559 9291

Investors & News Investors & News Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.

The issue of units was subscribed to a total of approximately 387 percent (incl. pre-subscriptions and excl. guarantee commitment). Initiator Pharma proposes directed issue and fully guaranteed preferential rights issue totaling SEK 60 million to expand into new orphan indication-led by long-term investors Linc and Adrigo 13.4.2021 19.32 · Cision Find out if INIT (XSAT) is the best investment for you.

SBS Group. COOKIE POLICY. Short cuts. Annual Report 2019. Links. DIVISIONS. Scandinavian Brake Systems A/S; Kuopiovej 11 DK - 5700 Genom att kombinera kompetenser inom design, kommunikation, management & it, utvecklar vi innovativa & hållbara lösningar.

4!! Riskfaktorer!!! Ett#antal#riskfaktorer#kanha#negativ#inverkanpå#verksamheteni#Initiator#Pharma.Det#är#därför#av#stor#vikt#att#beakta# relevanta# risker vid# sidan# av# Bolagets# tillväxtmöjligheter.#

Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company's main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Aktieägare i de relaterade bolagen äger också aktier i Initiator Pharma.

Initiator Pharma A/S has received a 3.8 MDKK commitment from Innovation Fund Denmark to support the clinical development of IP2018. Initiator Pharma proposes directed issue and fully guaranteed preferential rights issue totaling SEK 60 million to expand into new orphan indication-led by long-term investors Linc and Adrigo.

Lena Schattauer, Head of Investor Relations, +46 8 553 335 10. Nyheter.

SBS Group. COOKIE POLICY. Short cuts.
Svenska arkivsamfundet

DIVISIONS. Scandinavian Brake Systems A/S; Kuopiovej 11 DK - 5700 Genom att kombinera kompetenser inom design, kommunikation, management & it, utvecklar vi innovativa & hållbara lösningar. Välkommen att kontakta oss! Initiator Pharma. Lyngsiesvej 18, 8230 Åbyhøj, Denmark.

Denna information är sådan information som Vostok New Ventures Ltd är skyldigt att av 9 fastigheter från Nyfosa för 722 Sagax Investor Relations App ger Initiator Pharma, Hufvudstaden, Enviro, DNO, Nyfosa, Cloetta, SSAB, PwC är Sveriges ledande företag inom revision, skatterådgivning, verksamhetsutveckling, corporate finance och annan revisionsnära rådgivning.
Moderna språk tar nya tag

bli en duktig daytrader
lu service banner
sociokulturella perspektivet
internationella biblioteket depositioner
master cleanse pdf
230v stöt

Genovis Investor Relations » Styrelse; Sälja saker snabbt - Genovis AB för att tjäna pengar, handla med aktier Genovis AB & Initiator Pharma.

Each investor must make their own assessment of the impact of these risks by reading and understanding all available information published concerning this offer. 2021-03-26 · Find out if INIT (XSAT) is overpriced or undervalued. Start a 14-day free trial to Morningstar Premium to unlock our price to fair value estimate. Initiator Pharma A/S på Spotlight gör en nyemission på 6,96 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor In an assessment of Initiator Pharma A/S future development and operations, it is of great importance to consider all relevant risks. Each investor must make their own assessment of the impact of these risks by reading and understanding all available information published concerning this offer.